Feature Updates

Utilize Synapse Database to Explore Translational Medicine!

23 April 2024
4 min read

The Synapse Database for Translational Medicine is now live, come and experience it!

What are the characteristics of the Synapse database in transforming medicine?

Comprehensive Data Coverage 

Utilizing AI technology and an expert team, the Synapse database integrates the latest research materials from top global research institutions, medical facilities, and academic journals into translational medicine. Currently, it primarily encompasses data from 11 leading journals (such as Nature, Cell, Lancet, JMC, etc.) and abstracts from over 10 prestigious conferences (including ASCO, AACR, EULAR, ASH, and others).

Accurate Literature Search

Through advanced search algorithms, literature from around the globe can be rapidly categorized into 12 major topics including epidemiology, pathogenesis, targets/biomarkers, etc., and it extracts key information such as drugs, targets, indications, drug types, institutions, technologies, and research highlights. This enables quick localization and in-depth exploration of literature related to translational medicine.

Intelligent Analytical Views 

Provide real-time data analysis tools to help users gain insights into research trends and grasp industry dynamics. Aggregate the number of medical literature publications by years of issuance, ranking top targets, indications, and drug types to understand research trends.

Taking obesity as an example, one can observe that GLP-1R treatments for obesity have been quite popular over the past three years, and as of 2023, there are still preclinical studies ongoing. Additionally, new potential targets have emerged, such as PSD95, APOL6, etc.

图片包含 图标

描述已自动生成

Based on the number of published papers in various topics of translational medicine, conduct a cross-analysis of targets, indications, and drug types to understand research directions. Taking siRNA as an example, its research scope has already spanned multiple therapeutic areas.

Based on the number of translational medicine publications, a ranking of research institutions was conducted to identify current leaders in the field. Taking Alzheimer's disease as an example, Roche has conducted extensive basic research on Alzheimer's disease and has published numerous studies on disease mechanisms and targets.

Efficient Retrieval Methods

The Translational Medicine Data Section supports searches based upon various entity fields, spanning the T0 to T3 stages of translational phases. In addition, we offer search capabilities for conferences from previous years, as well as filter options, view modes, translation services, and highlights summaries.

Click on the image below to go directly to the Translational Medicine search interface.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Application Scenarios

1.New Target Discovery: Rapid identification of potential new targets using translational medicine data.

Latest Potential Targets in ALS Research: Enter ALS in the indications section of the translational medicine category. Select the topic "Targets/Biomarkers." A total of 67 translational medicine publications were found. Click search to access all publication details.

2. Discovering New Pathogenic Mechanisms for Diseases: Understanding the fundamental causes of diseases through basic research to provide new ideas for treatment.

Research on the Pathogenesis of Non-Small Cell Lung Cancer: In the translational medicine section under the indication for non-small cell lung cancer, the theme "pathogenic mechanism" has been highlighted, resulting in the retrieval of 30 translational medicine literature articles.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

3. Conduct in-depth research on the structure and function of targets.

PD-1 Structural and Functional Research: Enter PD-1 at the target section of the translational medicine segment, select Structural Biology as the focus, and search. The system will automatically provide the translation of the title and abstract of a research article. Clicking on the title will allow you to jump to and review the details of the article.

图形用户界面, 文本, 应用程序, 电子邮件, Teams

描述已自动生成

4. Search for the Latest Preclinical Research: Providing pharmaceutical R&D personnel and physicians with up-to-date clinical research information to aid clinical decision-making.

AACR 2024 Preclinical Research: Click on "Drug Discovery/Preclinical" in the translational medicine section, select AACR 2024 at the academic conference section, and click search to instantly find 795 pieces of translational medical literature.

图形用户界面, 文本, 应用程序

描述已自动生成

5.Technical Insight: Mining the Cutting-Edge Technologies in New Drug Development

Recent one-month technology literature mining: Click on "New Technology" in the section of Translational Medicine, select a publication date within one month, and hit search to instantly locate 668 pieces of translational medicine literature.

6.Research on Disease Epidemic Trends: Epidemiological studies can reveal the potential causes and risk factors of diseases, providing direction for scientific research efforts.

Experience the Synapse database now and embark on your journey into translational medicine!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Phase 3 SELECT-GCA Study: Upadacitinib Shows Promise in Treating Giant Cell Arteritis
Latest Hotspot
3 min read
Phase 3 SELECT-GCA Study: Upadacitinib Shows Promise in Treating Giant Cell Arteritis
23 April 2024
Results from the Phase 3 SELECT-GCA trial indicate that Upadacitinib (RINVOQ®) offers promising outcomes for individuals with Giant Cell Arteritis.
Read →
What are the requirements for the fragment length in the shRNA design process?
"What" Series
2 min read
What are the requirements for the fragment length in the shRNA design process?
23 April 2024
In the design process of shRNA (short hairpin RNA), the fragment length is an important consideration factor, as it can affect the efficiency and specificity of RNA interference (RNAi).
Read →
NMPA Approves HLX53 Anti-TIGIT Trial with HANSIZHUANG/HANBEITAI for Advanced Liver Cancer
Latest Hotspot
3 min read
NMPA Approves HLX53 Anti-TIGIT Trial with HANSIZHUANG/HANBEITAI for Advanced Liver Cancer
23 April 2024
NMPA Greenlights IND Submission for Initial Clinical Trial Using HLX53 Anti-TIGIT Fc Fusion Protein in Conjunction with HANSIZHUANG and HANBEITAI for Early Treatment in Patients with Advanced or Metastatic Liver Cancer.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 23
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 23
23 April 2024
April 23rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.